
https://www.science.org/content/blog-post/dark-matter-compound-collection
# Dark Matter Compound Collection (October 2015)

## 1. SUMMARY
This article discusses a Nature Chemical Biology paper by Novartis researchers introducing the concept of "dark chemical matter" (DCM)—compounds in screening libraries that have been tested in at least 100 different assays but never shown biological activity. Analysis of the Novartis collection (800,000 compounds tested in 234 assays) and NIH's Molecular Libraries collection (429 PubChem assays) revealed that 14% of consistently screened compounds remained completely inactive, a far higher percentage than would be expected by random chance. These DCM compounds tended to be more hydrophilic with fewer aromatic rings than active compounds, yet appeared structurally unremarkable to medicinal chemists. Surprisingly, these compounds weren't inactive due to poor cell permeability or purity issues, and when re-tested in additional assays, some did eventually hit—but at much lower rates than typical library compounds. The authors suggested that DCM compounds represent higher-quality hits when they do show activity, with better signal-to-noise ratios and less promiscuity.

## 2. HISTORY
The dark chemical matter concept has had significant impact on drug discovery practices since 2015:

**Academic and Industry Adoption**: The DCM framework has been widely adopted across pharmaceutical companies and academic screening centers. Major organizations including GSK, Pfizer, Merck, and academic consortia incorporated DCM analysis into their compound library management strategies. The approach influenced how compounds are selected for screening campaigns and how hit validation is performed.

**Publication Impact**: The original Nature Chemical Biology paper (Wassermann et al., 2015) has been cited over 400 times as of 2024, indicating substantial influence on subsequent research. Follow-up studies expanded the concept to different target classes, fragment-based drug discovery, and phenotypic screening approaches.

**Practical Implementation**: Pharmaceutical companies began systematically identifying and tracking DCM compounds in their collections. Some organizations created separate DCM subsets for specialized screening campaigns, particularly for assays with high false-positive rates. However, there's no evidence of any FDA-approved drugs originating specifically from DCM-focused campaigns, nor broad industry-wide adoption of DCM as the primary source of drug leads.

**Related Developments**: The concept contributed to broader discussions about library quality and diversity in drug discovery. It influenced subsequent work on privileged scaffolds, frequent hitters, and PAINS (pan-assay interference compounds). Research continues on understanding why certain chemical structures show consistently low activity across diverse biological targets.

**Limitations**: The DCM concept proved most valuable for understanding compound library composition and quality rather than as a direct source of new drug candidates. Most pharmaceutical companies continued their traditional approaches to hit identification while incorporating DCM awareness into their triage processes.

## 3. PREDICTIONS
- **Prediction**: "I hope to see some follow-up on its concepts from other organizations eventually"
  
  **Outcome**: ✅ **Accurate**. Numerous pharmaceutical companies and academic groups published follow-up studies examining DCM in their own collections and expanding the concept to different therapeutic areas and target classes.

- **Prediction**: The authors suggested DCM compounds "could present an opportunity for identifying new leads" with "little or no target promiscuity"
  
  **Outcome**: ⚠️ **Partially realized**. While the concept improved understanding of library quality and some DCM compounds were identified as quality hits, there's no clear evidence of widespread successful drug discovery campaigns specifically built around DCM prioritization. The main value proved to be in library characterization rather than as a primary source of drug leads.

- **Prediction**: DCM compounds would show different behavior "if you're going for antifungals or antibacterials" or "undruggable" targets like protein-protein interactions
  
  **Outcome**: ⚠️ **Partially explored**. Some subsequent studies examined DCM in antimicrobial screening, but comprehensive analysis across diverse target classes remains incomplete. No major breakthroughs in "undruggable" target drug discovery have been specifically attributed to DCM approaches.

## 4. INTEREST
**Score: 8/9**

This article addresses a fundamental issue in drug discovery methodology that affects billions of dollars in pharmaceutical R&D investment. The DCM concept provided a quantitative framework for understanding compound library quality that has influenced screening strategies across the industry for nearly a decade, making it highly impactful despite not yielding major therapeutic breakthroughs directly.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20151020-dark-matter-compound-collection.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_